Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug;100(8):1125-1144.
doi: 10.1007/s00109-022-02229-9. Epub 2022 Jul 11.

Functional roles of E3 ubiquitin ligases in prostate cancer

Yiting Zhao #  1   2   3 , Jinyun Li #  1   2 , Jun Chen  3 , Meng Ye  1   2 , Xiaofeng Jin  4   5
Affiliations
Review

Functional roles of E3 ubiquitin ligases in prostate cancer

Yiting Zhao et al. J Mol Med (Berl). 2022 Aug.

Abstract

Prostate cancer (PCa) is a malignant epithelial tumor of the prostate gland with a high male cancer incidence. Numerous studies indicate that abnormal function of ubiquitin-proteasome system (UPS) is associated with the progression and metastasis of PCa. E3 ubiquitin ligases, key components of UPS, determine the specificity of substrates, and substantial advances of E3 ubiquitin ligases have been reached recently. Herein, we introduce the structures and functions of E3 ubiquitin ligases and summarize the mechanisms of E3 ubiquitin ligases-related PCa signaling pathways. In addition, some progresses in the development of inhibitors targeting E3 ubiquitin ligases are also included.

Keywords: Castration-resistant prostate cancer (CRPC); E3 ubiquitin ligases; Prostate cancer (PCa); Signaling pathways; Targeted therapy.

PubMed Disclaimer

References

    1. Miller KD et al (2019) Cancer treatment and survivorship statistics. CA Cancer J Clin 69(2019):363–385. https://doi.org/10.3322/caac.21565 - DOI - PubMed
    1. Mottet N et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 Update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 79:243–262. https://doi.org/10.1016/j.eururo.2020.09.042
    1. Komura K, Sweeney CJ, Inamoto T, Ibuki N, Azuma H, Kantoff PW (2018) Current treatment strategies for advanced prostate cancer. Int J Urol 25:220–231. https://doi.org/10.1111/iju.13512 - DOI - PubMed
    1. Cornford P et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer, Eur Urol 71:630–642. https://doi.org/10.1016/j.eururo.2016.08.002 - DOI - PubMed
    1. Mori K et al (2020) Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 23:539–548. https://doi.org/10.1038/s41391-020-0222-6 - DOI - PubMed

Publication types

LinkOut - more resources